Back to results
US 8,475,793 B2Granted
Engineered anti-TSLPR antibodies
AssigneeMerck Sharp & Dohme Corp.
InventorsRene De Waal Malefyt, Leonard G. Presta
Life of this patent
Estimating the term…
Abstract
The invention relates to binding compounds that specifically bind to human TSLPR, as well as uses thereof, e.g., in the treatment of inflammatory disorders.
Claims4
A binding compound that specifically binds human and cyno TSLPR comprising:
- an antibody heavy chain variable region, or TSLPR-binding fragment thereof, comprising the CDR-H1 sequence of SEQ ID NO:1, the CDR-H2 sequence of SEQ ID NO:2 or SEQ ID NO:73, and the CDR-H3 sequence of SEQ ID NO:3;
- and
- an antibody light chain variable region, or TSLPR-binding fragment thereof, comprising the CDR-L1 sequence of SEQ ID NO:4, the CDR-L2 sequence of SEQ ID NO:5, and the CDR-L3 sequence of SEQ ID NO:6 or SEQ ID NO:74.
Dependencies are inferred from the claim text.